+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Pneumovax 23 Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

  • PDF Icon

    Report

  • 175 Pages
  • April 2025
  • Region: Global
  • The Business Research Company
  • ID: 6103978
The pneumovax 23 market research report is one of a series of new reports that provides pneumovax 23 market statistics, including the pneumovax 23 industry's global market size, regional shares, competitors with a pneumovax 23 market share, detailed pneumovax 23 market segments, market trends and opportunities, and any further data you may need to thrive in the pneumovax 23 industry. This pneumovax 23 market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The growth in the forecast period can be attributed to growing urbanization, rising number of aging populations, rising prevalence of co-morbidities, increasing healthcare infrastructure investments, and increasing use of digital health platforms. Major trends in the forecast period include advancements in vaccine cold chain management, development of needle-free vaccine delivery systems, integration of artificial intelligence and machine learning, advancements in vaccine packaging technologies, and personalized vaccine delivery systems.

The growing incidence of pneumococcal diseases is expected to drive the expansion of the Pneumovax 23 market in the coming years. Pneumococcal diseases are caused by the bacterium Streptococcus pneumoniae, which can result in a range of health problems, from mild issues such as sinus infections and ear infections to more severe conditions such as pneumonia and meningitis. These can sometimes lead to hospitalization. The rising incidence of pneumococcal diseases is influenced by factors such as decreased vaccination rates during the COVID-19 pandemic, the higher vulnerability of individuals with chronic health conditions, and the resurgence of respiratory infections as social restrictions have eased. Pneumovax 23 works by immunizing individuals against 23 strains of Streptococcus pneumoniae, thereby reducing the risk of infections such as pneumonia, meningitis, and bacteremia. For example, in January 2023, the Office for National Statistics reported that in December 2022, excess deaths in England due to influenza and pneumonia were 26.2% above the usual rate. This highlights the rising burden of pneumococcal diseases and is driving the growth of the Pneumovax 23 market.

The increasing rate of urbanization is also expected to contribute to the growth of the Pneumovax 23 market. Urbanization is largely driven by factors such as industrialization, which brings better job opportunities, enhanced access to healthcare, and a higher standard of living that attracts people from rural areas. As urban populations grow, so does their access to healthcare education and awareness campaigns. This can lead to higher vaccination rates as more people understand the importance of preventing pneumococcal diseases. According to a report by the World Bank Group in April 2023, approximately 56% of the global population, or about 4.4 billion people, currently live in urban areas, with that number expected to increase, potentially doubling by 2050. This rapid urbanization is further fueling demand for vaccines such as Pneumovax 23.

The expansion of government immunization programs is another key factor expected to drive the growth of the Pneumovax 23 market. Governments at the national and local levels often implement immunization programs to prevent vaccine-preventable diseases, boost vaccination coverage, and improve public health outcomes. These initiatives may include regular vaccination schedules, special campaigns, and efforts to raise public awareness. As governments work to fill gaps in immunization, especially those caused by the COVID-19 pandemic, they are increasing access to vaccines and ensuring equitable distribution. For example, a report by the UK Parliament in March 2024 stated that in 2022, the UK had an immunization rate of 90%, placing it 32nd among the 38 OECD member countries. With a focus on improving immunization rates, these government efforts are expected to further drive the demand for Pneumovax 23.

The key company operating in the pneumovax 23 market is Merck & Co. Inc. (Merck Sharp & Dohme Corp.)

North America was the largest region in the pneumovax 23 market in 2024. The regions covered in pneumovax 23 report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the pneumovax 23 market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Pneumovax 23 is a vaccine that provides protection against 23 different strains of pneumococcal bacteria, which are responsible for severe infections such as pneumonia, meningitis, and bloodstream infections. It is primarily recommended for older adults and individuals with certain medical conditions to help prevent invasive pneumococcal diseases. The vaccine works by stimulating the immune system to recognize and fight these bacterial strains, offering long-term immunity.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary formulations of Pneumovax 23 include the pneumococcal polysaccharide vaccine (PPV) and the pneumococcal conjugate vaccine (PCV). The pneumococcal polysaccharide vaccine (PPV) is specifically designed to protect against multiple pneumococcal strains using polysaccharides from bacterial capsules. Pneumovax 23, as a widely used PPV, defends against 23 strains of pneumococcal bacteria. It is commonly administered for the prevention of pneumococcal diseases and is used in settings such as hospitals, clinics, ambulatory surgical centers, and pharmacies.

The pneumovax 23 market consists of the sales of pneumovax 23 vaccine (the primary 23-valent pneumococcal polysaccharide vaccine). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.

Table of Contents

1. Executive Summary2. Pneumovax 23 Market Characteristics
3. Pneumovax 23 Market Biologic Drug Characteristics
3.1. Molecule Type
3.2. Route Of Administration (ROA)
3.3. Mechanism Of Action (MOA)
3.4. Safety And Efficacy
4. Pneumovax 23 Market Trends And Strategies5. Pneumovax 23 Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
6. Global Pneumovax 23 Growth Analysis And Strategic Analysis Framework
6.1. Global Pneumovax 23 PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
6.2. Analysis Of End Use Industries
6.3. Global Pneumovax 23 Market Growth Rate Analysis
6.4. Global Pneumovax 23 Historic Market Size and Growth, 2019 - 2024, Value ($ Million)
6.5. Global Pneumovax 23 Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Million)
6.6. Global Pneumovax 23 Total Addressable Market (TAM)
7. Global Pneumovax 23 Pricing Analysis & Forecasts
8. Pneumovax 23 Market Segmentation
8.1. Global Pneumovax 23 Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Pneumococcal Polysaccharide Vaccine (PPV)
  • Pneumococcal Conjugate Vaccine (PCV)
8.2. Global Pneumovax 23 Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Pneumococcal Disease Prevention
8.3. Global Pneumovax 23 Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • Pharmacies
9. Global Pneumovax 23 Epidemiology Of Clinical Indications
9.1. Drug Side Effects
9.2. Incidence And Prevalence of Clinical Indications
10. Pneumovax 23 Market Regional And Country Analysis
10.1. Global Pneumovax 23 Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
10.2. Global Pneumovax 23 Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
11. Asia-Pacific Pneumovax 23 Market
11.1. Asia-Pacific Pneumovax 23 Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Pneumovax 23 Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
11.3. Asia-Pacific Pneumovax 23 Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
11.4. Asia-Pacific Pneumovax 23 Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
12. China Pneumovax 23 Market
12.1. China Pneumovax 23 Market Overview
12.2. China Pneumovax 23 Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Million
12.3. China Pneumovax 23 Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Million
12.4. China Pneumovax 23 Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Million
13. India Pneumovax 23 Market
13.1. India Pneumovax 23 Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
13.2. India Pneumovax 23 Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
13.3. India Pneumovax 23 Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
14. Japan Pneumovax 23 Market
14.1. Japan Pneumovax 23 Market Overview
14.2. Japan Pneumovax 23 Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
14.3. Japan Pneumovax 23 Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
14.4. Japan Pneumovax 23 Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
15. Australia Pneumovax 23 Market
15.1. Australia Pneumovax 23 Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
15.2. Australia Pneumovax 23 Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
15.3. Australia Pneumovax 23 Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
16. South Korea Pneumovax 23 Market
16.1. South Korea Pneumovax 23 Market Overview
16.2. South Korea Pneumovax 23 Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
16.3. South Korea Pneumovax 23 Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
16.4. South Korea Pneumovax 23 Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
17. Western Europe Pneumovax 23 Market
17.1. Western Europe Pneumovax 23 Market Overview
17.2. Western Europe Pneumovax 23 Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
17.3. Western Europe Pneumovax 23 Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
17.4. Western Europe Pneumovax 23 Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
18. UK Pneumovax 23 Market
18.1. UK Pneumovax 23 Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
18.2. UK Pneumovax 23 Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
18.3. UK Pneumovax 23 Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
19. Germany Pneumovax 23 Market
19.1. Germany Pneumovax 23 Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
19.2. Germany Pneumovax 23 Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
19.3. Germany Pneumovax 23 Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
20. France Pneumovax 23 Market
20.1. France Pneumovax 23 Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
20.2. France Pneumovax 23 Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
20.3. France Pneumovax 23 Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
21. Eastern Europe Pneumovax 23 Market
21.1. Eastern Europe Pneumovax 23 Market Overview
21.2. Eastern Europe Pneumovax 23 Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
21.3. Eastern Europe Pneumovax 23 Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
21.4. Eastern Europe Pneumovax 23 Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
22. North America Pneumovax 23 Market
22.1. North America Pneumovax 23 Market Overview
22.2. North America Pneumovax 23 Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
22.3. North America Pneumovax 23 Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
22.4. North America Pneumovax 23 Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
23. USA Pneumovax 23 Market
23.1. USA Pneumovax 23 Market Overview
23.2. USA Pneumovax 23 Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
23.3. USA Pneumovax 23 Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
23.4. USA Pneumovax 23 Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
24. Canada Pneumovax 23 Market
24.1. Canada Pneumovax 23 Market Overview
24.2. Canada Pneumovax 23 Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
24.3. Canada Pneumovax 23 Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
24.4. Canada Pneumovax 23 Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
25. South America Pneumovax 23 Market
25.1. South America Pneumovax 23 Market Overview
25.2. South America Pneumovax 23 Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
25.3. South America Pneumovax 23 Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
25.4. South America Pneumovax 23 Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
26. Middle East Pneumovax 23 Market
26.1. Middle East Pneumovax 23 Market Overview
26.2. Middle East Pneumovax 23 Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
26.3. Middle East Pneumovax 23 Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
26.4. Middle East Pneumovax 23 Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
27. Africa Pneumovax 23 Market
27.1. Africa Pneumovax 23 Market Overview
27.2. Africa Pneumovax 23 Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
27.3. Africa Pneumovax 23 Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
27.4. Africa Pneumovax 23 Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
28. Pneumovax 23 Market Competitive Landscape And Company Profiles
28.1. Pneumovax 23 Market Competitive Landscape
28.2. Pneumovax 23 Market Company Profiles
28.2.1. Merck & Co. Inc. (Merck Sharp & Dohme Corp.) Overview, Products and Services, Strategy and Financial Analysis
29. Global Pneumovax 23 Market Pipeline Analysis
29.1. High Level Clinic Trail Information
30. Global Pneumovax 23 Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Pneumovax 23 Market32. Recent Developments In The Pneumovax 23 Market
33. Pneumovax 23 Market High Potential Countries, Segments and Strategies
33.1 Pneumovax 23 Market In 2029 - Countries Offering Most New Opportunities
33.2 Pneumovax 23 Market In 2029 - Segments Offering Most New Opportunities
33.3 Pneumovax 23 Market In 2029 - Growth Strategies
33.3.1 Market Trend Based Strategies
33.3.2 Competitor Strategies
34. Appendix
34.1. Abbreviations
34.2. Currencies
34.3. Historic And Forecast Inflation Rates
34.4. Research Inquiries
34.5. About the Analyst
34.6. Copyright And Disclaimer

Executive Summary

Pneumovax 23 Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pneumovax 23 market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase:

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Description

Where is the largest and fastest growing market for pneumovax 23 ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The pneumovax 23 market global report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:
  • The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

1) By Formulation: Pneumococcal Polysaccharide Vaccine (PPV); Pneumococcal Conjugate Vaccine (PCV)
2) By Clinical Indication: Pneumococcal Disease Prevention
3) By End User: Hospitals; Clinics; Ambulatory Surgical Centers; Pharmacies

Key Companies Profiled: Merck & Co. Inc. (Merck Sharp & Dohme Corp.)

Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.

Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Delivery Format: PDF, Word and Excel Data Dashboard.

Companies Mentioned

  • Merck & Co. Inc. (Merck Sharp & Dohme Corp.)